Integrated Solutions for Cancer Research

Advancements in basic and translational cancer research continue to fuel development of multi-pronged therapeutic strategies targeting established and emerging hallmarks of cancer (see diagram right). Your aim may be to investigate cancer’s genetic origins, establish the mechanism of action or clinical implications of tumor biomarkers, or develop a targeted pharmaceutical, biotherapeutic, or cellular therapy. Enzo’s diverse scientific expertise and manufacturing capabilities facilitate those aims, offering an extensive portfolio of products that serve the equally broad demands of the cancer research and translational discovery markets. Our continuing efforts to develop innovative platforms and research tools are focused on enabling a future with more hope, more collaboration, more discovery, and less disease.

• Modulate with high-purity small molecules & active proteins
• Label with proprietary DNA & RNA amplification & labeling technologies
• Detect with sensitive, widely-published biomarker ELISAs, antibodies & cell-based assays

Established hallmarks (blue text), emerging hallmarks (red), and enabling characteristics (green) of cancer, as defined by Hanahan and Weinberg. Cell, Volume 144, Issue 5, 646-674, 4 March 2011.